Sunitinib-platinum (IV) prodrug-1

Sunitinib-platinum (IV) prodrug-1 (Complex A) is a Pt (IV) prodrug based on Cisplatin , and this design aims to enable Pt (IV) to be reduced to active Pt (II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum (IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum (IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum (IV) prodrug-1 can be used for research on renal cell carcinoma[1].